Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.36 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.36 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.36 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.36 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.36 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.36 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.34 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.34 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.33 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.33 |
| ▸ | SLC13A5 | Q86YT5 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14110364 | 0.88 | CYP4F2 (0.41) | CYP4F2CYP4A11PTGER1PTGER4PTGER3 | |
| SCHEMBL14110466 | 0.87 | CYP4F2 (0.47) | CYP4F2CYP4A11PTGER1PTGER4PTGER3 | |
| SCHEMBL14110338 | 0.86 | CYP4F2 (0.36) | CYP4F2CYP4A11PTGER1PTGER4PTGER3 | |
| SCHEMBL14369971 | 0.83 | HDAC8 (0.37) | CYP4F2CYP4A11PTGER1PTGER4PTGER3 | |
| SCHEMBL14110360 | 0.80 | CSNK2A1 (0.42) | PTGER1PTGER4PTGER3PTGER2HDAC8 | |
| SCHEMBL15053570 | 0.77 | MTNR1A (0.35) | MTNR1AMTNR1BSTING1 | |
| SCHEMBL6209967 | 0.76 | CYP4F2 (0.53) | CYP4F2CYP4A11MTNR1AMTNR1B | |
| SCHEMBL8439136 | 0.75 | CYP4F2 (0.53) | CYP4F2CYP4A11MTNR1AMTNR1B | |
| SCHEMBL4893750 | 0.74 | MTNR1A (0.32) | CYP4F2CYP4A11MTNR1AMTNR1BSTING1 | |
| SCHEMBL21732908 | 0.74 | MTNR1A (0.44) | MTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080167310-A1 | MODULATORS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS (PPAR) | GOSSETT LYNN STACY | 2008-07-10 | — | — | US | disclosed |
| US-7282501-B2 | Modulators of peroxisome proliferator activated receptors (PPAR) | ELI LILLY AND COMPANY (US) | 2007-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167310-A1 | MODULATORS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS (PPAR) | PPARG, PPARA, PPARD | CYP4F2 304/4885CYP4A11 60/4885PTGER1 206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.